(Reuters) - Tus kws tsim tshuaj Danish Novo Nordisk tau hais rau hnub Monday nws tau pib tham los yuav tus tswj hwm hauv Fab Kis tus kws tsim khoom siv kho mob Biocorp.
Lub tuam txhab Danish tau hais tias nws tau nkag mus rau hauv kev sib tham tshwj xeeb nrog Bio Jag, Biocorp tus tswv lag luam tseem ceeb, rau kev yuav nws tshaj 45% ceg txheem ntseeg hauv Fabkis lub tuam txhab ntawm tus nqi ntawm 35.0 euros ($ 37.44) ib feem ntawm nyiaj ntsuab.
Tus nqi sawv cev rau tus nqi ntawm 19.5% tshaj Biocorp tus nqi kaw lag luam thaum Lub Rau Hli 2 thiab cov nqi pauv Biocorp ntawm kwv yees li 154 lab euros, cov tuam txhab tau hais.
Qee cov tswv cuab tsawg, sawv cev rau 19.0% ntawm cov peev txheej ntawm Biocorp, kuj tseem yuav hloov pauv mus rau Novo Nordisk thiab kev hloov pauv yuav ua raws li cov txheej txheem nyem tawm.
Qhov kev yuav khoom thaiv yuav tsum tshwm sim thaum lub quarter thib peb ntawm 2023 thiab kev ua ntawv thov tom ntej yuav tsum muaj nyob rau lub Cuaj Hli 2023, Novo tau hais.
($ 1 = 0.9349 euros)
(Qhia los ntawm Michal Aleksandrowicz hauv Gdansk; Hloov kho los ntawm Kim Coghill)
Tau qhov twg los: https://finance.yahoo.com/news/novo-nordisk-talks-buy-controlling-060333579.html